MW Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows
By Steve Goldstein
Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday.
The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage, instead of 2.4 milligrams. After 72 weeks, the higher dose version for people who weigh 113 kilograms (249 pounds) on average resulted in 20.7% weight loss after 72 weeks, compared to 17.4% with the lower dose version, and 2.4% with placebo.
The company said that a third of those with the higher dose achieved weight loss of at least 25% after 72 weeks, versus 16.7% on the lower dose and none on placebo.
The results of a trial of the higher-dose version on adults with type 2 diabetes and obesity are expected in a few months, Novo Nordisk said.
Novo Nordisk's stock (DK:NOVO.B) $(NVO)$ fell 2% in Copenhagen trade and are down 27% over the last three months.
Analysts at Argus Research said the stock is now trading at 22 times its estimated 2025 earnings, which is well below the five-year average of 31, after last year's disappointing trial study of the next-generation CagriSema drug. They rate the stock a buy with a $110 price target for the U.S.-listed shares.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
January 17, 2025 08:23 ET (13:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.